Difference between revisions of "GLOMERULONEPHRITIS-IgA NEPHROPATHY"
(Imported from text file) |
(Imported from text file) |
||
| Line 20: | Line 20: | ||
==Reference(s)== | ==Reference(s)== | ||
<references /> | <references /> | ||
<br/>Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. | <br/>Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.] | ||
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.] | |||
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | <br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | ||
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | <br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | ||
Latest revision as of 20:03, 13 March 2023
SUMMARY
1. Most common cause of primary glomerulonephritis: peaks at 2nd/3rd decades of life, 2:1 male to female predominance.
2. Presentation: macroscopic haematuria (40-50%), microscopic haematuria (30-40%), nephrotic syndrome/rapidly progressive GN (10%), malignant HTN, AKI.
3. assoc. with liver cirrhosis, coeliac disease, HIV, minimal change disease, membranous nephropathy, granulomatosis with polyangitis (GPA).
4. Biopsy indications: proteinuria > 1g/day, AKI, new HTN or rapidly increasing BP.
5. Biopsy shows deposits of IgA and complement in the mesangium and in the glomerular capillaries on immunofluorescence staining.
6. Good prognostic factors: SCr ≤111 μmol/L[1], normal BP[2]; proteinuria was the most important predictor of renal outcome[3]
, proteinuria <1g/day offered better prognosis[4].
7. Use ACEis or ARBs for proteinuria (> 0.5 g/d) and progressive disease; use corticosteroid therapy when there is persistent proteinuria (> 1 g/d) despite 6 months on an ACEI/ARB.
8. The STOP IgA Trial showed that additional immunosuppressive therapy did not provide kidney-related benefits in patients with high-risk IgA nephropathy.
Reference(s)
- ↑ Wakai et al (2006) A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. NDT
- ↑ Wakai et al (2006) A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. NDT
- ↑ Berthoux et al (2011) Predicting the risk for dialysis or death in IgA nephropathy. JASN
- ↑ Berthoux et al (2011) Predicting the risk for dialysis or death in IgA nephropathy. JASN
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
